Nature Communications

Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)

2025-11-03

Full text

DOI https://doi.org/10.1038/s41467-025-64660-z